Juva Life files a patent on a family of small non-cannabinoid molecules targeting inflammatory indications in the general public and in pharmaceuticals

0

VANCOUVER, British Columbia, October 14, 2021 (GLOBE NEWSWIRE) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life”, “Juva” or the “Company”), a California-based life sciences company focused on the research, development and commercialization of cannabis products, today announced the advancement of the JUVA-19 class of compounds in formal development.

JUVA-19 is a small, non-cannabinoid molecule isolated from cannabis with previously unrecognized broad-spectrum anti-inflammatory properties. Preclinical results demonstrate that JUVA-19 inhibits IL1-beta and TNF-alpha in a dose-dependent manner. In addition, the company has identified candidate targets compatible with the regulation of oxidative stress and inflammation.

Juva Life takes advantage of the large body of literature suggesting the therapeutic benefits of cannabis coupled with modern drug discovery and deep learning tools. The company’s strategy is to develop natural and semi-synthetic compositions alone and in combination for the general public anti-inflammatory market, and at the same time to chemically optimize the compositions for certain pharmaceutical indications.

The Company’s business strategy is to leverage its unique knowledge of the chemistry and anti-inflammatory mode of action of non-cannabinoid compositions contained in cannabis to develop safe and effective therapies. The company intends to develop products through in vivo preclinical validation studies and to partner with leading pharmaceutical and consumer companies in the search for anti-inflammatory bioactives for their product pipelines. On October 6, 2021, the company filed a provisional patent with the United States Patent and Trademark Office (USPTO) on the method of using natural compositions and composition of matter claims on semi-analogues. synthetic and unnatural synthetics.

Company CEO Doug Chloupek says, “We are delighted with the progress of our internal research and development activities. Mr. Chloupek continues, “Our next steps are to build on our early findings by profiling the Juva-019 class of compounds in benchmark in vivo inflammation models, paving the way for the development of evidence-based products. . “

In a separate news item, the Company is pleased to announce the appointment of Dr. Peter Beitsch to its Board of Directors, effective immediately.

Dr Beitsch has held numerous positions in national surgical societies including the American Society of Breast Surgeons, where he served as president of the society from 2013 to 2014, first chair of the 2001-4 membership committee, program director for 2005 annual meeting in Los Angeles, board member from 2006-9 and 2012-15. He served on the Executive Committee of the Society of Surgical Oncology 2008-2010, the General Surgical Oncology Committee of the American Board of Surgery, and was a member of the National Faculty of Ultrasound at the American College of Surgeons.

Dr Beitsch has made presentations internationally and is actively involved in breast cancer and melanoma research. He is the author of major articles in peer-reviewed medical journals including the New England Journal of Medicine, Journal of the American Medical Association, Proceedings of the National Academy of Science, Journal of Clinical Oncology, and Annals of Surgical Oncology.

Company CEO Doug Chloupek said, “I am very pleased to welcome Dr. Beitsch to our board of directors today. The timing is excellent as we expand our investigative efforts towards new and exciting compounds. Dr Beitsch has provided excellent advice and insight through his previous role as an adviser to the Society and we look forward to his expanded role.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder
Juva Vie Inc.
requests@juvalife.com

About Juva Vie Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life uses cutting edge science to discover, develop and market safe and effective cannabis products. The company is successfully executing its 2018 roadmap, initially starting with standardizing cultivation, extraction and formulation to provide consumers with repeatable benefits. Juva is building on these skills in natural product process chemistry to now include discovery pharmacology. The Company will leverage revenues from its retail operations to advance Juva-019 and other potentially valuable non-cannabinoid bioactives for consumer and pharmaceutical applications. Juva strives to bring the cannabis market against the industry’s next-generation business model. For more information: https://juvalife.com/.

For more information, please contact:
Juva Life Investor Relations
Phone. : +1 833-333-5882 (JUVA)
Email: surveys@juvalife.com

Forward-looking statement
This press release contains statements and information which, to the extent that they are not historical facts, may constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may include financial and other projections, as well as statements regarding future economic plans, objectives or performance, or the assumption underlying all of the foregoing. In some cases, forward-looking statements may be identified by words such as “could”, “would”, “could”, “will”, “probable”, “except”, “anticipate”, “believe”, “have the ‘intention “,” plan “,” forecast “,” project “,” estimate “,” prospect “, or its negative or other similar expressions concerning matters which are not historical facts. Examples of such statements include, without limitation, statements regarding the objectives and business plans of the Company; product development, marketing strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the Company. forward-looking information, including, without limitation, risks relating to the future business plans of the Company; the risks that the Company will not be able to retain key personnel; the risks that the Company will not be able to obtain financing on reasonable terms or not at all, as well as all the other risks described in the management report of the Company for the financial year ended December 31, 2020 under the section “Risks and uncertainties”. Therefore, readers should not place undue reliance on this forward-looking information. In addition, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the management of the Company to predict all of these factors and to assess in advance the impact of each of these factors on the business of the Company or the extent to which any factor, or a combination of factors, could cause actual results to differ materially from those contained in any forward-looking information. The Company assumes no obligation to update forward-looking information to reflect information or events subsequent to the date on which it is made or to reflect the occurrence of unforeseen events, except as required by law, including securities laws.

The CSE accepts no responsibility for the adequacy or accuracy of this release.


Source link

Share.

Leave A Reply